[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018更新版).实用肝脏病杂志,2018,21(2):177-186.
[2] Sinha RA,Bruinstroop E,Singh BK,et al.Thyroid hormones and thyromimetics:A new approach to nonalcoholic steatohepatitis? Hepatology,2020,72:770-771.
[3] Sinha RA,Bruinstroop E,Singh BK,et al.Nonalcoholic fatty liver disease and hypercholesterolemia:roles of thyroid hormones,metabolites,and agonists.Thyroid,2019,29:1173-1191.
[4] Guo Z,Li M,Han B,Qi X.Association of non-alcoholic fatty liver disease with thyroid function:A systematic review and meta-analysis.Dig Liver Dis,2018,50:1153-1162.
[5] Eshraghian A,Hamidian Jahromi A.Non-alcoholic fatty liver disease and thyroid dysfunction:a systematic review.World J Gastroenterol,2014,20:8102-8109.
[6] Pihlajamäki J,Boes T,Kim EY,et al.Thyroid hormone-related regulation of gene expression in human fatty liver.J Clin Endocrinol Metab,2009,94:3521-3529.
[7] Sinha RA,You SH,Zhou J,et al.Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy.J Clin Invest,2012,122:2428-2438.
[8] Bruinstroop E,Dalan R,Cao Y,et al.Low-dose levothyroxine reduces intrahepatic lipid content in patients with type 2 diabetes mellitus and NAFLD.J Clin Endocrinol Metab,2018,103:2698-2706.
[9] Harrison SA,Bashir MR,Guy CD,et al.Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis:a multicentre,randomised,double-blind,placebo-controlled,phase 2 trial.Lancet,2019,394:2012-2024.
[10] Patel J,Bettencourt R,Cui J,et al.Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis.Therap Adv Gastroenterol,2016,9:692-701. |
